Modular Medical, Inc. (NASDAQ: MODD) priced a registered direct offering of 750,000 shares of its common stock at $4.50 per share on April 19 2026, generating approximately $3.4 million in gross proceeds before fees and expenses.
The proceeds are earmarked for working capital, ongoing product development, and commercialization of the Pivot insulin pump platform. The company also intends to use the funds to address its cash burn and extend its runway as it prepares for regulatory clearance and market entry.
Modular Medical’s financial health has been described as weak, with rapid cash burn and a need for external financing. The company recently regained compliance with Nasdaq’s minimum bid price requirement and completed a 1‑for‑30 reverse stock split effective March 31 2026, both of which underscore the urgency of the capital raise.
Investors reacted negatively to the announcement, citing the dilution of existing shareholders and the offering’s pricing below the company’s recent trading level. The discount pricing signals the company’s willingness to accept less favorable terms to secure liquidity.
The capital raise supports the launch of the Pivot pump, the first tubeless patch pump targeting the “almost‑pumper” market. The product received FDA 510(k) clearance on April 9 2026, with shipments expected by the end of Q2 2026. This financing is part of a pattern of external capital raises that Modular Medical has pursued to fund its growth initiatives.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.